Cue Biopharma, Inc. (CUE) Covered Calls
You can sell covered calls on Cue Biopharma, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CUE (prices last updated Mon 4:16 PM ET):
| Cue Biopharma, Inc. (CUE) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 1.10 | -0.14 | 1.06 | 1.14 | 464K | - | 0.1 |
| Covered Calls For Cue Biopharma, Inc. (CUE) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 20 | 1 | 0.00 | 1.14 | -12.3% | -136.0% | |
| Jan 17 | 1 | 0.05 | 1.09 | -8.3% | -49.7% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
| 2. | SPY covered calls | 7. | XLF covered calls | 2. | CRVS covered calls | |
| 3. | EEM covered calls | 8. | KWEB covered calls | 3. | ANAB covered calls | |
| 4. | FXI covered calls | 9. | TLT covered calls | 4. | APP covered calls | |
| 5. | IWM covered calls | 10. | KRE covered calls | 5. | RCAT covered calls | |
Want more examples? CUBI Covered Calls | CUK Covered Calls
